ALNY
Alnylam Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +4.3% ·
share flow +0.3% ·
net new positions 0.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | 0 | 220.72K | $53.70M | n/a | n/a |
| Q2 2026 | 162 | +3 | 107.60M | $32.37B | +7 | −3 |
| Q1 2026 | 161 | -2 | 108.78M | $35.89B | +4 | −7 |
| Q4 2025 | 162 | -2 | 118.83M | $47.26B | +1 | −2 |
| Q3 2025 | 24 | +1 | 85.59M | $39.02B | +2 | −2 |
| Q2 2025 | 21 | -1 | 76.99M | $25.10B | n/a | −1 |
| Q1 2025 | 19 | +2 | 40.24M | $10.86B | +3 | −1 |
| Q4 2024 | 17 | 0 | 41.95M | $9.87B | n/a | n/a |
| Q3 2024 | 16 | +1 | 39.28M | $10.80B | +2 | −1 |
| Q2 2024 | 15 | n/a | 40.30M | $9.79B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 16.77M | +6.1% | $7.65B | 0.4% | ▲ Add | 2 | SEC ↗ ×7 |
| 2 | Capital World Investors ✦ | 16.43M | -2.2% | $7.49B | 1.0% | ▼ Trim | 6 | SEC ↗ |
| 3 | The Vanguard Group ✦ (passive) | 13.57M | +2.0% | $6.19B | 0.1% | ▲ Add | 2 | SEC ↗ ×6 |
| 4 | BlackRock ✦ (passive) | 9.90M | -0.8% | $4.52B | 0.1% | ▼ Trim | 2 | SEC ↗ ×22 |
| 5 | JPMorgan Chase ✦ | 9.09M | n/a | $4.14B | 0.1% | n/c | 1 | SEC ↗ ×40 |
| 6 | State Street Global Advisors ✦ (passive) | 3.08M | -2.9% | $1.41B | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 7 | Baillie Gifford ✦ | 2.79M | -8.0% | $1.27B | 0.9% | ▼ Trim | 6 | SEC ↗ ×4 |
| 8 | Geode Capital Management ✦ (passive) | 2.50M | +4.2% | $1.14B | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Dodge & Cox ✦ | 2.32M | -27.4% | $1.06B | 0.6% | ▼ Trim | 6 | SEC ↗ |
| 10 | Wellington Management ✦ | 1.83M | -12.0% | $832.80M | 0.1% | ▼ Trim | 6 | SEC ↗ ×8 |
| 11 | T. Rowe Price ✦ | 1.80M | -42.8% | $820.93M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 12 | Arrowstreet Capital ✦ | 1.36M | +698.8% | $618.16M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 744.01K | +295.2% | $336.01M | 0.2% | ▲ Add | 6 | SEC ↗ ×8 |
| 14 | Morgan Stanley ✦ | 726.06K | n/a | $331.09M | 0.0% | n/c | 1 | SEC ↗ ×15 |
| 15 | Two Sigma Investments ✦ | 595.93K | +73.6% | $271.74M | 0.4% | ▲ Add | 6 | SEC ↗ |
| 16 | Millennium Management ✦ | 549.93K | +508.0% | $250.77M | 0.2% | ▲ Add | 6 | SEC ↗ |
| 17 | Goldman Sachs Group ✦ | 538.35K | n/a | $245.49M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 18 | Marshall Wace ✦ | 508.37K | +113.1% | $231.82M | 0.3% | ▲ Add | 5 | SEC ↗ ×3 |
| 19 | Citadel Advisors ✦ | 221.84K | -63.1% | $101.16M | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 20 | D. E. Shaw & Co. ✦ | 199.42K | +84.2% | $90.93M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 21 | Bridgewater Associates ✦ | 33.91K | New | $15.46M | 0.1% | New | 1 | SEC ↗ |
| 22 | Gotham Asset Management ✦ | 28.14K | +58.2% | $12.83M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 23 | Point72 Asset Management ✦ | 6.20K | -96.9% | $2.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 24 | Soros Fund Management ✦ | 4.29K | New | $1.96M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Bridgewater Associates | $15.46M | 0.1% |
| Soros Fund Management | $1.96M | 0.0% |
Exited
| Norges Bank | $662.84M | was 0.1% |
| Adage Capital Partners | $27.52M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 781 holders, 122.25M shares, $37.95B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 1.76K sh · $398,855
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology